Ipca LaboratoriesNSE:IPCALAB +3.46%90 Days Inventory is 360.32 as of Mar. 2026, which is 29% above its 10-year median of 279.21. GuruFocus rates NSE:IPCALAB with a GF Score™ of 90/100 and a GF Value™ of ₹1,598.63 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 918 Drug Manufacturers companies, Ipca Laboratories ranks worse than 88.45% on this metric.
The historical rank and industry rank for Ipca Laboratories's Days Inventory or its related term are showing as below:
NSE:IPCALAB'
s Days Inventory Range Over the Past 10 Years
Min: 255.85 Med: 279.21 Max: 342.11
Current: 336.51
During the past 13 years, Ipca Laboratories's highest Days Inventory was 342.11. The lowest was 255.85. And the median was 279.21.
NSE:IPCALAB's Days Inventory is ranked worse than 88.45% of 918
companies
in the Drug Manufacturers industry
Industry Median: 164.43
vs NSE:IPCALAB: 336.51
Ipca Laboratories's Days Inventory
increased
from Mar. 2025 (329.86) to Mar. 2026 (360.32).
It might indicate that Ipca Laboratories's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Ipca Laboratories's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.25.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ipca Laboratories's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.14.
Ipca Laboratories (NSE:IPCALAB) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ipca Laboratories's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ipca Laboratories's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Ipca Laboratories Days Inventory Related Terms
Ipca Laboratories Days Inventory Historical Data
* Premium members only.
The historical data trend for Ipca Laboratories's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:IPCALAB vs ZTS, UTHR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipca Laboratories Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's Days Inventory distribution charts can be found below:
* The bar in red indicates where Ipca Laboratories's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipca Laboratories (NSE:IPCALAB) has a Days Inventory of 360.32 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Ipca Laboratories and its competitors. This is 29% above median its historical median of 279.21. Over the past decade, Ipca Laboratories' Days Inventory has ranged from 255.85 to 342.11. According to the industry distribution chart, Ipca Laboratories ranks #812 out of 918 companies in the Drug Manufacturers industry, placing it in the top 88.5%.
Is Ipca Laboratories' Days Inventory too high?
Ipca Laboratories' current Days Inventory of 360.32 is 29% above median its 10-year median of 279.21. Over the past 10 years, this metric has ranged from a low of 255.85 to a high of 342.11. The Drug Manufacturers industry median Days Inventory is 164.43. Ipca Laboratories' value of 360.32 is 119.1% above this industry median. Based on the distribution chart, Ipca Laboratories ranks #812 out of 918 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ipca Laboratories has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipca Laboratories ranks #812 out of 918 companies for Days Inventory. This places Ipca Laboratories in the lower half of its industry. The industry median Days Inventory is 164.43. Ipca Laboratories' value of 360.32 is 119.1% above this benchmark. Historically, Ipca Laboratories' own Days Inventory has ranged from 255.85 to 342.11 over the past decade. While the company's 10-year median is 279.21 vs. the industry median of 164.43, Ipca Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipca Laboratories's current Days Inventory of 360.32 is 119.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Ipca Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipca Laboratories's current Days Inventory is 360.32, which is 29% above median its own 10-year median of 279.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,598.63, compared to a current price of ₹1,778.90 — trading 11.3% above its estimated fair value. The current Days Inventory is 360.32, which is 29% above median its 10-year median of 279.21 and 119.1% above the Drug Manufacturers industry median of 164.43. Ipca Laboratories' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current Days Inventory is 360.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued.
The current stock price of ₹1,778.90 is trading 11.3% above its estimated GF Value™ of ₹1,598.63.
GuruFocus considers Ipca Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:IPCALAB:
Days Inventory: 360.32 (29% above median its 10-year median of 279.21)
GF Value™: ₹1,598.63 vs. price of ₹1,778.90 (11.3% above fair value)
Industry Position: 119.1% above the Drug Manufacturers median (#812 of 918)
No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
90GF Score
Get the complete analysis for NSE:IPCALAB
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IPCALAB has been successfully added to your 
